文献速递药疹与重症皮肤不良反应

药物超敏反应综合征/伴嗜酸性粒细胞增多和系统症状的药疹:诊断与管理

Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part II diagnosis and management.
PubMed 文献 · J Am Acad Dermatol · 2023-07-28

本文为继续医学教育第二部分,阐述药物超敏反应综合征/伴嗜酸性粒细胞增多和系统症状的药疹的鉴别诊断与诊断,并基于证据概述评估与治疗。管理核心是立即停用可疑药物,全身性糖皮质激素仍为一线治疗,推荐对后遗症进行纵向评估。

要点

  • 鉴别诊断包括其他皮肤不良反应、感染、炎症性及自身免疫性疾病和肿瘤性疾病。
  • 已提出三套诊断标准,但尚缺乏共识。
  • 管理核心是立即停用可疑药物,全身性糖皮质激素仍为一线治疗。

核心结论

  • 药物超敏反应综合征/伴嗜酸性粒细胞增多和系统症状的药疹管理核心是立即停用可疑药物,全身性糖皮质激素仍为一线治疗。
  • literature on steroid-sparing agents is expanding,推荐对后遗症进行纵向评估。

研究设计与样本

  • 本文为继续医学教育活动的第二部分,基于证据概述评估与治疗。

主要发现

  • 已提出三套诊断标准,但尚缺乏共识。
  • 辅助检查用于风险分层和明确致病药物仍在研究中。

关键数值与推荐

  • 全身性糖皮质激素仍为一线治疗。
  • 推荐对后遗症进行纵向评估。

临床怎么用

  • 立即停用可疑药物是管理的基石。
  • 全身性糖皮质激素仍为一线治疗,保留激素制剂 literature 正在扩展。
  • 推荐对后遗症进行纵向评估。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Drug-induced hypersensitivity syndrome, also known as drug reaction with eosinophilia and systemic symptoms, is a severe cutaneous adverse reaction characterized by an exanthem, fever, and hematologic and visceral organ involvement. The differential diagnosis includes other cutaneous adverse reactions, infections, inflammatory and autoimmune diseases, and neoplastic disorders. Three sets of diagnostic criteria have been proposed; however, consensus is lacking. The cornerstone of management is immediate discontinuation of the suspected drug culprit. Systemic corticosteroids remain first-line therapy, but the literature on steroid-sparing agents is expanding. Longitudinal evaluation for sequelae is recommended. Adjunctive tests for risk stratification and drug culprit identification remain under investigation. Part II of this continuing medical education activity begins by exploring the differential diagnosis and diagnosis of drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms and concludes with an evidence-based overview of evaluation and treatment.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Wei BM, Fox LP, Kaffenberger BH, et al. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part II diagnosis and management. J Am Acad Dermatol. 2023. PMID: 37516356. doi:10.1016/j.jaad.2023.02.073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。